nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—PDGFRA—malignant glioma	0.244	0.409	CbGaD
Nilotinib—BRAF—malignant glioma	0.223	0.374	CbGaD
Nilotinib—CYP2B6—malignant glioma	0.129	0.216	CbGaD
Nilotinib—Brain oedema—Carmustine—malignant glioma	0.0023	0.0242	CcSEcCtD
Nilotinib—Brain oedema—Temozolomide—malignant glioma	0.00222	0.0234	CcSEcCtD
Nilotinib—Hyperaemia—Carmustine—malignant glioma	0.00218	0.0229	CcSEcCtD
Nilotinib—MAPK8—endothelium—malignant glioma	0.00204	0.0205	CbGeAlD
Nilotinib—MAPK8—blood vessel—malignant glioma	0.00188	0.0189	CbGeAlD
Nilotinib—TIE1—endothelium—malignant glioma	0.00177	0.0178	CbGeAlD
Nilotinib—Ponatinib—FGFR1—malignant glioma	0.00176	0.279	CrCbGaD
Nilotinib—TIE1—blood vessel—malignant glioma	0.00163	0.0164	CbGeAlD
Nilotinib—Haemorrhage intracranial—Temozolomide—malignant glioma	0.00155	0.0163	CcSEcCtD
Nilotinib—Myelosuppression—Carmustine—malignant glioma	0.0014	0.0148	CcSEcCtD
Nilotinib—Ponatinib—PDGFRA—malignant glioma	0.00136	0.215	CrCbGaD
Nilotinib—Myelosuppression—Temozolomide—malignant glioma	0.00135	0.0143	CcSEcCtD
Nilotinib—EPHB2—brainstem—malignant glioma	0.00128	0.0129	CbGeAlD
Nilotinib—Transient ischaemic attack—Temozolomide—malignant glioma	0.00126	0.0133	CcSEcCtD
Nilotinib—Lymphopenia—Temozolomide—malignant glioma	0.00124	0.0131	CcSEcCtD
Nilotinib—EPHB2—retina—malignant glioma	0.00124	0.0125	CbGeAlD
Nilotinib—EPHB4—endothelium—malignant glioma	0.00123	0.0124	CbGeAlD
Nilotinib—MAPK14—blood vessel—malignant glioma	0.00119	0.012	CbGeAlD
Nilotinib—TEK—endothelium—malignant glioma	0.00117	0.0118	CbGeAlD
Nilotinib—EPHB2—telencephalon—malignant glioma	0.00114	0.0115	CbGeAlD
Nilotinib—EPHB4—blood vessel—malignant glioma	0.00113	0.0114	CbGeAlD
Nilotinib—MAPK8—embryo—malignant glioma	0.00112	0.0113	CbGeAlD
Nilotinib—EPHA2—blood vessel—malignant glioma	0.00111	0.0112	CbGeAlD
Nilotinib—Skin hyperpigmentation—Carmustine—malignant glioma	0.00111	0.0116	CcSEcCtD
Nilotinib—CDC42BPB—retina—malignant glioma	0.0011	0.011	CbGeAlD
Nilotinib—Febrile neutropenia—Carmustine—malignant glioma	0.00109	0.0115	CcSEcCtD
Nilotinib—TEK—blood vessel—malignant glioma	0.00108	0.0109	CbGeAlD
Nilotinib—Haemorrhoids—Temozolomide—malignant glioma	0.00108	0.0114	CcSEcCtD
Nilotinib—Visual acuity reduced—Temozolomide—malignant glioma	0.00107	0.0112	CcSEcCtD
Nilotinib—Ponatinib—KDR—malignant glioma	0.00106	0.167	CrCbGaD
Nilotinib—Febrile neutropenia—Temozolomide—malignant glioma	0.00106	0.0111	CcSEcCtD
Nilotinib—EPHA3—retina—malignant glioma	0.00104	0.0105	CbGeAlD
Nilotinib—Oral candidiasis—Carmustine—malignant glioma	0.00103	0.0109	CcSEcCtD
Nilotinib—MAPK8—brainstem—malignant glioma	0.00103	0.0103	CbGeAlD
Nilotinib—MAPK11—telencephalon—malignant glioma	0.00102	0.0102	CbGeAlD
Nilotinib—Imatinib—NTRK1—malignant glioma	0.00101	0.16	CrCbGaD
Nilotinib—CDC42BPB—telencephalon—malignant glioma	0.00101	0.0102	CbGeAlD
Nilotinib—Oral candidiasis—Temozolomide—malignant glioma	0.001	0.0105	CcSEcCtD
Nilotinib—MAPK8—retina—malignant glioma	0.00099	0.00998	CbGeAlD
Nilotinib—Cyst—Carmustine—malignant glioma	0.000983	0.0104	CcSEcCtD
Nilotinib—Interstitial lung disease—Carmustine—malignant glioma	0.000929	0.00978	CcSEcCtD
Nilotinib—Thrombosis—Carmustine—malignant glioma	0.000929	0.00978	CcSEcCtD
Nilotinib—EPHB3—embryo—malignant glioma	0.000924	0.00931	CbGeAlD
Nilotinib—MAPK8—telencephalon—malignant glioma	0.000911	0.00918	CbGeAlD
Nilotinib—MAP4K1—retina—malignant glioma	0.0009	0.00907	CbGeAlD
Nilotinib—Interstitial lung disease—Temozolomide—malignant glioma	0.000898	0.00945	CcSEcCtD
Nilotinib—Menorrhagia—Temozolomide—malignant glioma	0.000858	0.00904	CcSEcCtD
Nilotinib—Hepatotoxicity—Carmustine—malignant glioma	0.000851	0.00896	CcSEcCtD
Nilotinib—KIT—endothelium—malignant glioma	0.00085	0.00856	CbGeAlD
Nilotinib—EPHB3—brainstem—malignant glioma	0.000847	0.00853	CbGeAlD
Nilotinib—Imatinib—PDGFRA—malignant glioma	0.000837	0.132	CrCbGaD
Nilotinib—Cholestasis—Temozolomide—malignant glioma	0.000837	0.00881	CcSEcCtD
Nilotinib—Hepatotoxicity—Temozolomide—malignant glioma	0.000823	0.00866	CcSEcCtD
Nilotinib—Hyperaesthesia—Temozolomide—malignant glioma	0.000809	0.00852	CcSEcCtD
Nilotinib—CDC42BPB—medulla oblongata—malignant glioma	0.000792	0.00798	CbGeAlD
Nilotinib—KIT—blood vessel—malignant glioma	0.000784	0.0079	CbGeAlD
Nilotinib—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.000772	0.00813	CcSEcCtD
Nilotinib—Petechiae—Temozolomide—malignant glioma	0.000772	0.00813	CcSEcCtD
Nilotinib—EPHA4—embryo—malignant glioma	0.000772	0.00778	CbGeAlD
Nilotinib—Endocrine disorder—Temozolomide—malignant glioma	0.000766	0.00807	CcSEcCtD
Nilotinib—PDGFRB—blood vessel—malignant glioma	0.000765	0.00771	CbGeAlD
Nilotinib—EPHB3—telencephalon—malignant glioma	0.000751	0.00757	CbGeAlD
Nilotinib—Disturbance in attention—Temozolomide—malignant glioma	0.000733	0.00772	CcSEcCtD
Nilotinib—Breast pain—Temozolomide—malignant glioma	0.000728	0.00767	CcSEcCtD
Nilotinib—CDC42BPB—midbrain—malignant glioma	0.000723	0.00729	CbGeAlD
Nilotinib—MAPK8—medulla oblongata—malignant glioma	0.000716	0.00721	CbGeAlD
Nilotinib—MAPK14—embryo—malignant glioma	0.000711	0.00717	CbGeAlD
Nilotinib—FGR—embryo—malignant glioma	0.000709	0.00714	CbGeAlD
Nilotinib—EPHA4—brainstem—malignant glioma	0.000707	0.00713	CbGeAlD
Nilotinib—CDC42BPB—spinal cord—malignant glioma	0.000706	0.00711	CbGeAlD
Nilotinib—Leukocytosis—Carmustine—malignant glioma	0.000699	0.00736	CcSEcCtD
Nilotinib—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.000699	0.00735	CcSEcCtD
Nilotinib—HCK—telencephalon—malignant glioma	0.00069	0.00696	CbGeAlD
Nilotinib—Herpes simplex—Temozolomide—malignant glioma	0.000689	0.00726	CcSEcCtD
Nilotinib—Hearing impaired—Temozolomide—malignant glioma	0.000667	0.00703	CcSEcCtD
Nilotinib—Neck pain—Carmustine—malignant glioma	0.000665	0.007	CcSEcCtD
Nilotinib—MAPK8—midbrain—malignant glioma	0.000654	0.00659	CbGeAlD
Nilotinib—MAPK14—brainstem—malignant glioma	0.000652	0.00657	CbGeAlD
Nilotinib—EPHB2—central nervous system—malignant glioma	0.000648	0.00653	CbGeAlD
Nilotinib—TEK—embryo—malignant glioma	0.000645	0.0065	CbGeAlD
Nilotinib—Musculoskeletal pain—Temozolomide—malignant glioma	0.000643	0.00677	CcSEcCtD
Nilotinib—MAPK8—spinal cord—malignant glioma	0.000638	0.00643	CbGeAlD
Nilotinib—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000635	0.00669	CcSEcCtD
Nilotinib—Urinary incontinence—Carmustine—malignant glioma	0.000635	0.00668	CcSEcCtD
Nilotinib—Skin exfoliation—Carmustine—malignant glioma	0.000628	0.00661	CcSEcCtD
Nilotinib—Candida infection—Carmustine—malignant glioma	0.000628	0.00661	CcSEcCtD
Nilotinib—EPHA4—telencephalon—malignant glioma	0.000628	0.00632	CbGeAlD
Nilotinib—EPHA8—central nervous system—malignant glioma	0.000621	0.00626	CbGeAlD
Nilotinib—CA3—telencephalon—malignant glioma	0.00062	0.00625	CbGeAlD
Nilotinib—Influenza like illness—Temozolomide—malignant glioma	0.000617	0.0065	CcSEcCtD
Nilotinib—Urinary incontinence—Temozolomide—malignant glioma	0.000613	0.00646	CcSEcCtD
Nilotinib—EPHA8—cerebellum—malignant glioma	0.000607	0.00612	CbGeAlD
Nilotinib—Candida infection—Temozolomide—malignant glioma	0.000606	0.00639	CcSEcCtD
Nilotinib—Skin exfoliation—Temozolomide—malignant glioma	0.000606	0.00639	CcSEcCtD
Nilotinib—Neoplasm—Carmustine—malignant glioma	0.000594	0.00626	CcSEcCtD
Nilotinib—Gynaecomastia—Carmustine—malignant glioma	0.000588	0.00619	CcSEcCtD
Nilotinib—Dry eye—Temozolomide—malignant glioma	0.000587	0.00618	CcSEcCtD
Nilotinib—PDGFRA—embryo—malignant glioma	0.000585	0.00589	CbGeAlD
Nilotinib—MAPK14—telencephalon—malignant glioma	0.000579	0.00583	CbGeAlD
Nilotinib—MAPK11—central nervous system—malignant glioma	0.000577	0.00582	CbGeAlD
Nilotinib—Neoplasm—Temozolomide—malignant glioma	0.000574	0.00605	CcSEcCtD
Nilotinib—CDC42BPB—central nervous system—malignant glioma	0.000573	0.00577	CbGeAlD
Nilotinib—Sepsis—Carmustine—malignant glioma	0.00057	0.00601	CcSEcCtD
Nilotinib—MAPK11—cerebellum—malignant glioma	0.000564	0.00569	CbGeAlD
Nilotinib—CA14—telencephalon—malignant glioma	0.000563	0.00567	CbGeAlD
Nilotinib—CDC42BPB—cerebellum—malignant glioma	0.00056	0.00564	CbGeAlD
Nilotinib—Diabetes mellitus—Carmustine—malignant glioma	0.000549	0.00578	CcSEcCtD
Nilotinib—EPHB4—telencephalon—malignant glioma	0.000549	0.00553	CbGeAlD
Nilotinib—BRAF—midbrain—malignant glioma	0.000544	0.00548	CbGeAlD
Nilotinib—EPHA3—central nervous system—malignant glioma	0.000543	0.00547	CbGeAlD
Nilotinib—HCK—medulla oblongata—malignant glioma	0.000543	0.00547	CbGeAlD
Nilotinib—Ear pain—Temozolomide—malignant glioma	0.00054	0.00569	CcSEcCtD
Nilotinib—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00053	0.00558	CcSEcCtD
Nilotinib—Eye pain—Carmustine—malignant glioma	0.000529	0.00556	CcSEcCtD
Nilotinib—EPHB3—spinal cord—malignant glioma	0.000526	0.00531	CbGeAlD
Nilotinib—TEK—telencephalon—malignant glioma	0.000525	0.00529	CbGeAlD
Nilotinib—Gastroenteritis—Temozolomide—malignant glioma	0.00052	0.00548	CcSEcCtD
Nilotinib—MAPK8—central nervous system—malignant glioma	0.000518	0.00522	CbGeAlD
Nilotinib—EPHA6—central nervous system—malignant glioma	0.000518	0.00522	CbGeAlD
Nilotinib—Deafness—Temozolomide—malignant glioma	0.000515	0.00543	CcSEcCtD
Nilotinib—CSF1R—embryo—malignant glioma	0.000515	0.00519	CbGeAlD
Nilotinib—EPHB2—brain—malignant glioma	0.000514	0.00518	CbGeAlD
Nilotinib—Eye pain—Temozolomide—malignant glioma	0.000511	0.00538	CcSEcCtD
Nilotinib—Amnesia—Carmustine—malignant glioma	0.000508	0.00535	CcSEcCtD
Nilotinib—MAPK8—cerebellum—malignant glioma	0.000506	0.0051	CbGeAlD
Nilotinib—EPHB6—telencephalon—malignant glioma	0.000502	0.00506	CbGeAlD
Nilotinib—HCK—midbrain—malignant glioma	0.000496	0.005	CbGeAlD
Nilotinib—EPHA4—medulla oblongata—malignant glioma	0.000493	0.00497	CbGeAlD
Nilotinib—EPHA8—brain—malignant glioma	0.000493	0.00497	CbGeAlD
Nilotinib—Amnesia—Temozolomide—malignant glioma	0.000491	0.00517	CcSEcCtD
Nilotinib—CA7—midbrain—malignant glioma	0.000485	0.00489	CbGeAlD
Nilotinib—HCK—spinal cord—malignant glioma	0.000484	0.00488	CbGeAlD
Nilotinib—MAP2K5—brainstem—malignant glioma	0.000483	0.00487	CbGeAlD
Nilotinib—Hyponatraemia—Carmustine—malignant glioma	0.000479	0.00504	CcSEcCtD
Nilotinib—LYN—central nervous system—malignant glioma	0.000478	0.00482	CbGeAlD
Nilotinib—Diplopia—Carmustine—malignant glioma	0.000477	0.00502	CcSEcCtD
Nilotinib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000477	0.00502	CcSEcCtD
Nilotinib—PDGFRA—telencephalon—malignant glioma	0.000476	0.00479	CbGeAlD
Nilotinib—KIT—embryo—malignant glioma	0.000467	0.00471	CbGeAlD
Nilotinib—Diplopia—Temozolomide—malignant glioma	0.000461	0.00485	CcSEcCtD
Nilotinib—Face oedema—Carmustine—malignant glioma	0.000461	0.00485	CcSEcCtD
Nilotinib—MAPK11—brain—malignant glioma	0.000458	0.00462	CbGeAlD
Nilotinib—PDGFRB—embryo—malignant glioma	0.000457	0.0046	CbGeAlD
Nilotinib—CDC42BPB—brain—malignant glioma	0.000455	0.00458	CbGeAlD
Nilotinib—TIE1—central nervous system—malignant glioma	0.000449	0.00452	CbGeAlD
Nilotinib—Face oedema—Temozolomide—malignant glioma	0.000445	0.00469	CcSEcCtD
Nilotinib—CA14—medulla oblongata—malignant glioma	0.000442	0.00446	CbGeAlD
Nilotinib—CA12—telencephalon—malignant glioma	0.000439	0.00442	CbGeAlD
Nilotinib—TIE1—cerebellum—malignant glioma	0.000439	0.00442	CbGeAlD
Nilotinib—Hypokalaemia—Carmustine—malignant glioma	0.000434	0.00457	CcSEcCtD
Nilotinib—EPHB4—medulla oblongata—malignant glioma	0.000431	0.00434	CbGeAlD
Nilotinib—EPHA3—brain—malignant glioma	0.000431	0.00434	CbGeAlD
Nilotinib—MAP2K5—telencephalon—malignant glioma	0.000429	0.00432	CbGeAlD
Nilotinib—Dehydration—Temozolomide—malignant glioma	0.000429	0.00451	CcSEcCtD
Nilotinib—KIT—brainstem—malignant glioma	0.000428	0.00432	CbGeAlD
Nilotinib—EPHB3—central nervous system—malignant glioma	0.000427	0.0043	CbGeAlD
Nilotinib—Dry skin—Temozolomide—malignant glioma	0.000423	0.00445	CcSEcCtD
Nilotinib—Muscular weakness—Carmustine—malignant glioma	0.000421	0.00443	CcSEcCtD
Nilotinib—BRAF—cerebellum—malignant glioma	0.000421	0.00424	CbGeAlD
Nilotinib—Hypokalaemia—Temozolomide—malignant glioma	0.00042	0.00442	CcSEcCtD
Nilotinib—CSF1R—telencephalon—malignant glioma	0.000419	0.00422	CbGeAlD
Nilotinib—EPHB3—cerebellum—malignant glioma	0.000417	0.00421	CbGeAlD
Nilotinib—Breast disorder—Temozolomide—malignant glioma	0.000417	0.00439	CcSEcCtD
Nilotinib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000415	0.00437	CcSEcCtD
Nilotinib—TEK—medulla oblongata—malignant glioma	0.000412	0.00416	CbGeAlD
Nilotinib—MAPK8—brain—malignant glioma	0.000411	0.00414	CbGeAlD
Nilotinib—EPHA6—brain—malignant glioma	0.000411	0.00414	CbGeAlD
Nilotinib—ABL1—embryo—malignant glioma	0.000407	0.0041	CbGeAlD
Nilotinib—Muscular weakness—Temozolomide—malignant glioma	0.000407	0.00428	CcSEcCtD
Nilotinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000407	0.00428	CcSEcCtD
Nilotinib—MAPK14—spinal cord—malignant glioma	0.000405	0.00409	CbGeAlD
Nilotinib—CA14—midbrain—malignant glioma	0.000404	0.00407	CbGeAlD
Nilotinib—Abdominal distension—Temozolomide—malignant glioma	0.000401	0.00422	CcSEcCtD
Nilotinib—CA14—spinal cord—malignant glioma	0.000394	0.00397	CbGeAlD
Nilotinib—EPHB6—medulla oblongata—malignant glioma	0.000394	0.00397	CbGeAlD
Nilotinib—EPHB4—midbrain—malignant glioma	0.000394	0.00397	CbGeAlD
Nilotinib—HCK—central nervous system—malignant glioma	0.000392	0.00396	CbGeAlD
Nilotinib—Pancytopenia—Carmustine—malignant glioma	0.000392	0.00412	CcSEcCtD
Nilotinib—Neutropenia—Carmustine—malignant glioma	0.000386	0.00406	CcSEcCtD
Nilotinib—EPHB4—spinal cord—malignant glioma	0.000384	0.00387	CbGeAlD
Nilotinib—Bronchitis—Temozolomide—malignant glioma	0.000383	0.00404	CcSEcCtD
Nilotinib—ABL2—cerebellum—malignant glioma	0.000381	0.00384	CbGeAlD
Nilotinib—KIT—telencephalon—malignant glioma	0.00038	0.00383	CbGeAlD
Nilotinib—LYN—brain—malignant glioma	0.000379	0.00382	CbGeAlD
Nilotinib—Pancytopenia—Temozolomide—malignant glioma	0.000378	0.00398	CcSEcCtD
Nilotinib—TEK—midbrain—malignant glioma	0.000377	0.0038	CbGeAlD
Nilotinib—CA7—cerebellum—malignant glioma	0.000375	0.00378	CbGeAlD
Nilotinib—MAP4K1—brain—malignant glioma	0.000374	0.00377	CbGeAlD
Nilotinib—ABL1—brainstem—malignant glioma	0.000373	0.00376	CbGeAlD
Nilotinib—Dysuria—Temozolomide—malignant glioma	0.000373	0.00392	CcSEcCtD
Nilotinib—Neutropenia—Temozolomide—malignant glioma	0.000373	0.00392	CcSEcCtD
Nilotinib—Hyperglycaemia—Carmustine—malignant glioma	0.000372	0.00392	CcSEcCtD
Nilotinib—PDGFRB—telencephalon—malignant glioma	0.000371	0.00374	CbGeAlD
Nilotinib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00037	0.0039	CcSEcCtD
Nilotinib—Pneumonia—Carmustine—malignant glioma	0.00037	0.00389	CcSEcCtD
Nilotinib—Pollakiuria—Temozolomide—malignant glioma	0.000368	0.00388	CcSEcCtD
Nilotinib—TEK—spinal cord—malignant glioma	0.000368	0.00371	CbGeAlD
Nilotinib—Erectile dysfunction—Temozolomide—malignant glioma	0.000367	0.00386	CcSEcCtD
Nilotinib—Photosensitivity reaction—Temozolomide—malignant glioma	0.000364	0.00383	CcSEcCtD
Nilotinib—Weight increased—Temozolomide—malignant glioma	0.000363	0.00382	CcSEcCtD
Nilotinib—Renal failure—Carmustine—malignant glioma	0.000361	0.00381	CcSEcCtD
Nilotinib—Weight decreased—Temozolomide—malignant glioma	0.000361	0.0038	CcSEcCtD
Nilotinib—Neuropathy peripheral—Carmustine—malignant glioma	0.00036	0.00379	CcSEcCtD
Nilotinib—EPHB6—midbrain—malignant glioma	0.00036	0.00363	CbGeAlD
Nilotinib—ABL1—retina—malignant glioma	0.00036	0.00363	CbGeAlD
Nilotinib—Hyperglycaemia—Temozolomide—malignant glioma	0.00036	0.00379	CcSEcCtD
Nilotinib—Stomatitis—Carmustine—malignant glioma	0.000358	0.00377	CcSEcCtD
Nilotinib—Urinary tract infection—Carmustine—malignant glioma	0.000357	0.00376	CcSEcCtD
Nilotinib—Pneumonia—Temozolomide—malignant glioma	0.000357	0.00376	CcSEcCtD
Nilotinib—EPHA4—central nervous system—malignant glioma	0.000357	0.00359	CbGeAlD
Nilotinib—TIE1—brain—malignant glioma	0.000356	0.00359	CbGeAlD
Nilotinib—Infestation NOS—Temozolomide—malignant glioma	0.000355	0.00374	CcSEcCtD
Nilotinib—Infestation—Temozolomide—malignant glioma	0.000355	0.00374	CcSEcCtD
Nilotinib—CA3—central nervous system—malignant glioma	0.000352	0.00355	CbGeAlD
Nilotinib—EPHB6—spinal cord—malignant glioma	0.000351	0.00354	CbGeAlD
Nilotinib—EPHA4—cerebellum—malignant glioma	0.000349	0.00351	CbGeAlD
Nilotinib—Neuropathy peripheral—Temozolomide—malignant glioma	0.000348	0.00367	CcSEcCtD
Nilotinib—CA1—telencephalon—malignant glioma	0.000348	0.0035	CbGeAlD
Nilotinib—Stomatitis—Temozolomide—malignant glioma	0.000346	0.00365	CcSEcCtD
Nilotinib—Urinary tract infection—Temozolomide—malignant glioma	0.000345	0.00364	CcSEcCtD
Nilotinib—BRAF—brain—malignant glioma	0.000342	0.00344	CbGeAlD
Nilotinib—EPHB3—brain—malignant glioma	0.000339	0.00342	CbGeAlD
Nilotinib—MAP2K5—medulla oblongata—malignant glioma	0.000337	0.0034	CbGeAlD
Nilotinib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000336	0.00354	CcSEcCtD
Nilotinib—PDGFRA—spinal cord—malignant glioma	0.000333	0.00336	CbGeAlD
Nilotinib—Haemoglobin—Carmustine—malignant glioma	0.000332	0.00349	CcSEcCtD
Nilotinib—ABL1—telencephalon—malignant glioma	0.000331	0.00334	CbGeAlD
Nilotinib—Haemorrhage—Carmustine—malignant glioma	0.00033	0.00348	CcSEcCtD
Nilotinib—CA9—cerebellum—malignant glioma	0.00033	0.00332	CbGeAlD
Nilotinib—CSF1R—medulla oblongata—malignant glioma	0.000329	0.00332	CbGeAlD
Nilotinib—MAPK14—central nervous system—malignant glioma	0.000329	0.00331	CbGeAlD
Nilotinib—Hypoaesthesia—Carmustine—malignant glioma	0.000328	0.00346	CcSEcCtD
Nilotinib—FGR—central nervous system—malignant glioma	0.000328	0.0033	CbGeAlD
Nilotinib—Oedema peripheral—Carmustine—malignant glioma	0.000325	0.00342	CcSEcCtD
Nilotinib—Connective tissue disorder—Carmustine—malignant glioma	0.000324	0.00342	CcSEcCtD
Nilotinib—MAPK14—cerebellum—malignant glioma	0.000321	0.00324	CbGeAlD
Nilotinib—Haemoglobin—Temozolomide—malignant glioma	0.000321	0.00338	CcSEcCtD
Nilotinib—Haemorrhage—Temozolomide—malignant glioma	0.000319	0.00336	CcSEcCtD
Nilotinib—Hepatitis—Temozolomide—malignant glioma	0.000319	0.00336	CcSEcCtD
Nilotinib—Visual impairment—Carmustine—malignant glioma	0.000318	0.00335	CcSEcCtD
Nilotinib—Hypoaesthesia—Temozolomide—malignant glioma	0.000317	0.00334	CcSEcCtD
Nilotinib—Pharyngitis—Temozolomide—malignant glioma	0.000317	0.00333	CcSEcCtD
Nilotinib—Urinary tract disorder—Temozolomide—malignant glioma	0.000315	0.00332	CcSEcCtD
Nilotinib—Oedema peripheral—Temozolomide—malignant glioma	0.000314	0.00331	CcSEcCtD
Nilotinib—Connective tissue disorder—Temozolomide—malignant glioma	0.000313	0.0033	CcSEcCtD
Nilotinib—Urethral disorder—Temozolomide—malignant glioma	0.000313	0.00329	CcSEcCtD
Nilotinib—CA14—cerebellum—malignant glioma	0.000313	0.00315	CbGeAlD
Nilotinib—HCK—brain—malignant glioma	0.000312	0.00314	CbGeAlD
Nilotinib—ABL2—brain—malignant glioma	0.00031	0.00312	CbGeAlD
Nilotinib—Eye disorder—Carmustine—malignant glioma	0.000309	0.00325	CcSEcCtD
Nilotinib—MAP2K5—midbrain—malignant glioma	0.000308	0.0031	CbGeAlD
Nilotinib—Visual impairment—Temozolomide—malignant glioma	0.000307	0.00324	CcSEcCtD
Nilotinib—Flushing—Carmustine—malignant glioma	0.000306	0.00323	CcSEcCtD
Nilotinib—CA4—brainstem—malignant glioma	0.000306	0.00309	CbGeAlD
Nilotinib—EPHA2—central nervous system—malignant glioma	0.000306	0.00308	CbGeAlD
Nilotinib—CA7—brain—malignant glioma	0.000305	0.00307	CbGeAlD
Nilotinib—EPHB4—cerebellum—malignant glioma	0.000305	0.00307	CbGeAlD
Nilotinib—Erythema multiforme—Temozolomide—malignant glioma	0.000302	0.00318	CcSEcCtD
Nilotinib—CSF1R—midbrain—malignant glioma	0.000301	0.00303	CbGeAlD
Nilotinib—MAP2K5—spinal cord—malignant glioma	0.000301	0.00303	CbGeAlD
Nilotinib—KIT—medulla oblongata—malignant glioma	0.000299	0.00301	CbGeAlD
Nilotinib—TEK—central nervous system—malignant glioma	0.000298	0.00301	CbGeAlD
Nilotinib—Eye disorder—Temozolomide—malignant glioma	0.000298	0.00314	CcSEcCtD
Nilotinib—Tinnitus—Temozolomide—malignant glioma	0.000297	0.00313	CcSEcCtD
Nilotinib—Flushing—Temozolomide—malignant glioma	0.000296	0.00312	CcSEcCtD
Nilotinib—Cardiac disorder—Temozolomide—malignant glioma	0.000296	0.00312	CcSEcCtD
Nilotinib—Arrhythmia—Carmustine—malignant glioma	0.000295	0.0031	CcSEcCtD
Nilotinib—CSF1R—spinal cord—malignant glioma	0.000293	0.00296	CbGeAlD
Nilotinib—PDGFRB—medulla oblongata—malignant glioma	0.000292	0.00294	CbGeAlD
Nilotinib—Alopecia—Carmustine—malignant glioma	0.000292	0.00307	CcSEcCtD
Nilotinib—TEK—cerebellum—malignant glioma	0.000292	0.00294	CbGeAlD
Nilotinib—Imatinib—PTGS1—malignant glioma	0.000291	0.0461	CrCbGaD
Nilotinib—Angiopathy—Temozolomide—malignant glioma	0.000289	0.00305	CcSEcCtD
Nilotinib—Mental disorder—Carmustine—malignant glioma	0.000289	0.00304	CcSEcCtD
Nilotinib—Immune system disorder—Temozolomide—malignant glioma	0.000288	0.00303	CcSEcCtD
Nilotinib—Mediastinal disorder—Temozolomide—malignant glioma	0.000288	0.00303	CcSEcCtD
Nilotinib—Malnutrition—Carmustine—malignant glioma	0.000287	0.00303	CcSEcCtD
Nilotinib—Erythema—Carmustine—malignant glioma	0.000287	0.00303	CcSEcCtD
Nilotinib—Chills—Temozolomide—malignant glioma	0.000286	0.00301	CcSEcCtD
Nilotinib—EPHB6—central nervous system—malignant glioma	0.000285	0.00287	CbGeAlD
Nilotinib—EPHA4—brain—malignant glioma	0.000283	0.00285	CbGeAlD
Nilotinib—Alopecia—Temozolomide—malignant glioma	0.000282	0.00297	CcSEcCtD
Nilotinib—CA3—brain—malignant glioma	0.00028	0.00282	CbGeAlD
Nilotinib—Mental disorder—Temozolomide—malignant glioma	0.000279	0.00294	CcSEcCtD
Nilotinib—EPHB6—cerebellum—malignant glioma	0.000279	0.00281	CbGeAlD
Nilotinib—Back pain—Carmustine—malignant glioma	0.000278	0.00293	CcSEcCtD
Nilotinib—Erythema—Temozolomide—malignant glioma	0.000278	0.00292	CcSEcCtD
Nilotinib—Malnutrition—Temozolomide—malignant glioma	0.000278	0.00292	CcSEcCtD
Nilotinib—CA2—embryo—malignant glioma	0.000277	0.00279	CbGeAlD
Nilotinib—KIT—midbrain—malignant glioma	0.000273	0.00275	CbGeAlD
Nilotinib—Dysgeusia—Temozolomide—malignant glioma	0.000272	0.00286	CcSEcCtD
Nilotinib—CA4—telencephalon—malignant glioma	0.000272	0.00274	CbGeAlD
Nilotinib—Vision blurred—Carmustine—malignant glioma	0.000271	0.00285	CcSEcCtD
Nilotinib—PDGFRA—central nervous system—malignant glioma	0.00027	0.00272	CbGeAlD
Nilotinib—Tremor—Carmustine—malignant glioma	0.000269	0.00283	CcSEcCtD
Nilotinib—Back pain—Temozolomide—malignant glioma	0.000269	0.00283	CcSEcCtD
Nilotinib—PDGFRB—midbrain—malignant glioma	0.000267	0.00269	CbGeAlD
Nilotinib—KIT—spinal cord—malignant glioma	0.000266	0.00268	CbGeAlD
Nilotinib—Anaemia—Carmustine—malignant glioma	0.000266	0.0028	CcSEcCtD
Nilotinib—PDGFRA—cerebellum—malignant glioma	0.000264	0.00266	CbGeAlD
Nilotinib—Vision blurred—Temozolomide—malignant glioma	0.000262	0.00276	CcSEcCtD
Nilotinib—MAPK14—brain—malignant glioma	0.000261	0.00263	CbGeAlD
Nilotinib—Tremor—Temozolomide—malignant glioma	0.00026	0.00274	CcSEcCtD
Nilotinib—PDGFRB—spinal cord—malignant glioma	0.00026	0.00262	CbGeAlD
Nilotinib—ABL1—medulla oblongata—malignant glioma	0.00026	0.00262	CbGeAlD
Nilotinib—FGR—brain—malignant glioma	0.00026	0.00262	CbGeAlD
Nilotinib—Ill-defined disorder—Temozolomide—malignant glioma	0.000258	0.00271	CcSEcCtD
Nilotinib—Leukopenia—Carmustine—malignant glioma	0.000257	0.00271	CcSEcCtD
Nilotinib—Anaemia—Temozolomide—malignant glioma	0.000257	0.0027	CcSEcCtD
Nilotinib—CA14—brain—malignant glioma	0.000254	0.00256	CbGeAlD
Nilotinib—CA2—brainstem—malignant glioma	0.000254	0.00256	CbGeAlD
Nilotinib—Malaise—Temozolomide—malignant glioma	0.00025	0.00264	CcSEcCtD
Nilotinib—Vertigo—Temozolomide—malignant glioma	0.00025	0.00263	CcSEcCtD
Nilotinib—CA12—central nervous system—malignant glioma	0.000249	0.00251	CbGeAlD
Nilotinib—Leukopenia—Temozolomide—malignant glioma	0.000249	0.00262	CcSEcCtD
Nilotinib—Hypertension—Carmustine—malignant glioma	0.000248	0.00261	CcSEcCtD
Nilotinib—EPHB4—brain—malignant glioma	0.000248	0.00249	CbGeAlD
Nilotinib—Palpitations—Temozolomide—malignant glioma	0.000245	0.00258	CcSEcCtD
Nilotinib—CA2—retina—malignant glioma	0.000245	0.00247	CbGeAlD
Nilotinib—Chest pain—Carmustine—malignant glioma	0.000245	0.00258	CcSEcCtD
Nilotinib—Myalgia—Carmustine—malignant glioma	0.000245	0.00258	CcSEcCtD
Nilotinib—MAP2K5—central nervous system—malignant glioma	0.000244	0.00246	CbGeAlD
Nilotinib—Anxiety—Carmustine—malignant glioma	0.000244	0.00257	CcSEcCtD
Nilotinib—CA1—spinal cord—malignant glioma	0.000244	0.00246	CbGeAlD
Nilotinib—EPHA2—brain—malignant glioma	0.000243	0.00245	CbGeAlD
Nilotinib—Cough—Temozolomide—malignant glioma	0.000242	0.00255	CcSEcCtD
Nilotinib—Hypertension—Temozolomide—malignant glioma	0.00024	0.00252	CcSEcCtD
Nilotinib—MAP2K5—cerebellum—malignant glioma	0.000238	0.0024	CbGeAlD
Nilotinib—CSF1R—central nervous system—malignant glioma	0.000238	0.0024	CbGeAlD
Nilotinib—ABL1—midbrain—malignant glioma	0.000238	0.0024	CbGeAlD
Nilotinib—TEK—brain—malignant glioma	0.000237	0.00239	CbGeAlD
Nilotinib—Confusional state—Carmustine—malignant glioma	0.000236	0.00249	CcSEcCtD
Nilotinib—Arthralgia—Temozolomide—malignant glioma	0.000236	0.00249	CcSEcCtD
Nilotinib—Myalgia—Temozolomide—malignant glioma	0.000236	0.00249	CcSEcCtD
Nilotinib—Anxiety—Temozolomide—malignant glioma	0.000236	0.00248	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000235	0.00247	CcSEcCtD
Nilotinib—Oedema—Carmustine—malignant glioma	0.000235	0.00247	CcSEcCtD
Nilotinib—Discomfort—Temozolomide—malignant glioma	0.000234	0.00246	CcSEcCtD
Nilotinib—Infection—Carmustine—malignant glioma	0.000233	0.00245	CcSEcCtD
Nilotinib—CSF1R—cerebellum—malignant glioma	0.000233	0.00234	CbGeAlD
Nilotinib—ABL1—spinal cord—malignant glioma	0.000232	0.00234	CbGeAlD
Nilotinib—Dry mouth—Temozolomide—malignant glioma	0.000231	0.00243	CcSEcCtD
Nilotinib—Thrombocytopenia—Carmustine—malignant glioma	0.00023	0.00242	CcSEcCtD
Nilotinib—Tachycardia—Carmustine—malignant glioma	0.000229	0.00241	CcSEcCtD
Nilotinib—Confusional state—Temozolomide—malignant glioma	0.000229	0.00241	CcSEcCtD
Nilotinib—Oedema—Temozolomide—malignant glioma	0.000227	0.00239	CcSEcCtD
Nilotinib—EPHB6—brain—malignant glioma	0.000226	0.00228	CbGeAlD
Nilotinib—CA2—telencephalon—malignant glioma	0.000225	0.00227	CbGeAlD
Nilotinib—Infection—Temozolomide—malignant glioma	0.000225	0.00237	CcSEcCtD
Nilotinib—Anorexia—Carmustine—malignant glioma	0.000224	0.00235	CcSEcCtD
Nilotinib—Nervous system disorder—Temozolomide—malignant glioma	0.000222	0.00234	CcSEcCtD
Nilotinib—Thrombocytopenia—Temozolomide—malignant glioma	0.000222	0.00234	CcSEcCtD
Nilotinib—Skin disorder—Temozolomide—malignant glioma	0.00022	0.00232	CcSEcCtD
Nilotinib—Hypotension—Carmustine—malignant glioma	0.000219	0.00231	CcSEcCtD
Nilotinib—Hyperhidrosis—Temozolomide—malignant glioma	0.000219	0.00231	CcSEcCtD
Nilotinib—KIT—central nervous system—malignant glioma	0.000216	0.00218	CbGeAlD
Nilotinib—Anorexia—Temozolomide—malignant glioma	0.000216	0.00227	CcSEcCtD
Nilotinib—PDGFRA—brain—malignant glioma	0.000215	0.00216	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000214	0.00225	CcSEcCtD
Nilotinib—CA4—medulla oblongata—malignant glioma	0.000214	0.00215	CbGeAlD
Nilotinib—ABCB1—blood vessel—malignant glioma	0.000212	0.00214	CbGeAlD
Nilotinib—Insomnia—Carmustine—malignant glioma	0.000212	0.00223	CcSEcCtD
Nilotinib—KIT—cerebellum—malignant glioma	0.000211	0.00213	CbGeAlD
Nilotinib—PDGFRB—central nervous system—malignant glioma	0.000211	0.00213	CbGeAlD
Nilotinib—Paraesthesia—Carmustine—malignant glioma	0.000211	0.00222	CcSEcCtD
Nilotinib—Dyspnoea—Carmustine—malignant glioma	0.000209	0.0022	CcSEcCtD
Nilotinib—ABCG2—telencephalon—malignant glioma	0.000209	0.0021	CbGeAlD
Nilotinib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000206	0.00217	CcSEcCtD
Nilotinib—PDGFRB—cerebellum—malignant glioma	0.000206	0.00208	CbGeAlD
Nilotinib—Insomnia—Temozolomide—malignant glioma	0.000205	0.00216	CcSEcCtD
Nilotinib—Decreased appetite—Carmustine—malignant glioma	0.000204	0.00215	CcSEcCtD
Nilotinib—Paraesthesia—Temozolomide—malignant glioma	0.000204	0.00214	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000202	0.00213	CcSEcCtD
Nilotinib—Dyspnoea—Temozolomide—malignant glioma	0.000202	0.00213	CcSEcCtD
Nilotinib—Pain—Carmustine—malignant glioma	0.000201	0.00211	CcSEcCtD
Nilotinib—Constipation—Carmustine—malignant glioma	0.000201	0.00211	CcSEcCtD
Nilotinib—Dyspepsia—Temozolomide—malignant glioma	0.0002	0.0021	CcSEcCtD
Nilotinib—CA12—brain—malignant glioma	0.000198	0.002	CbGeAlD
Nilotinib—CA1—central nervous system—malignant glioma	0.000198	0.00199	CbGeAlD
Nilotinib—Decreased appetite—Temozolomide—malignant glioma	0.000197	0.00207	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000196	0.00206	CcSEcCtD
Nilotinib—Fatigue—Temozolomide—malignant glioma	0.000195	0.00206	CcSEcCtD
Nilotinib—CA4—midbrain—malignant glioma	0.000195	0.00197	CbGeAlD
Nilotinib—Pain—Temozolomide—malignant glioma	0.000194	0.00204	CcSEcCtD
Nilotinib—Constipation—Temozolomide—malignant glioma	0.000194	0.00204	CcSEcCtD
Nilotinib—MAP2K5—brain—malignant glioma	0.000194	0.00195	CbGeAlD
Nilotinib—Feeling abnormal—Carmustine—malignant glioma	0.000193	0.00203	CcSEcCtD
Nilotinib—Gastrointestinal pain—Carmustine—malignant glioma	0.000192	0.00202	CcSEcCtD
Nilotinib—CA4—spinal cord—malignant glioma	0.00019	0.00192	CbGeAlD
Nilotinib—CSF1R—brain—malignant glioma	0.000189	0.0019	CbGeAlD
Nilotinib—ABL1—central nervous system—malignant glioma	0.000188	0.0019	CbGeAlD
Nilotinib—Feeling abnormal—Temozolomide—malignant glioma	0.000187	0.00197	CcSEcCtD
Nilotinib—Abdominal pain—Carmustine—malignant glioma	0.000185	0.00195	CcSEcCtD
Nilotinib—Body temperature increased—Carmustine—malignant glioma	0.000185	0.00195	CcSEcCtD
Nilotinib—Gastrointestinal pain—Temozolomide—malignant glioma	0.000185	0.00195	CcSEcCtD
Nilotinib—ABL1—cerebellum—malignant glioma	0.000184	0.00185	CbGeAlD
Nilotinib—Urticaria—Temozolomide—malignant glioma	0.00018	0.0019	CcSEcCtD
Nilotinib—Abdominal pain—Temozolomide—malignant glioma	0.000179	0.00189	CcSEcCtD
Nilotinib—Body temperature increased—Temozolomide—malignant glioma	0.000179	0.00189	CcSEcCtD
Nilotinib—CA2—medulla oblongata—malignant glioma	0.000177	0.00178	CbGeAlD
Nilotinib—Hypersensitivity—Carmustine—malignant glioma	0.000173	0.00182	CcSEcCtD
Nilotinib—KIT—brain—malignant glioma	0.000172	0.00173	CbGeAlD
Nilotinib—Asthenia—Carmustine—malignant glioma	0.000168	0.00177	CcSEcCtD
Nilotinib—PDGFRB—brain—malignant glioma	0.000168	0.00169	CbGeAlD
Nilotinib—Hypersensitivity—Temozolomide—malignant glioma	0.000167	0.00176	CcSEcCtD
Nilotinib—ABCG2—medulla oblongata—malignant glioma	0.000164	0.00165	CbGeAlD
Nilotinib—Asthenia—Temozolomide—malignant glioma	0.000163	0.00171	CcSEcCtD
Nilotinib—CA2—midbrain—malignant glioma	0.000162	0.00163	CbGeAlD
Nilotinib—CYP2D6—brainstem—malignant glioma	0.000161	0.00162	CbGeAlD
Nilotinib—Diarrhoea—Carmustine—malignant glioma	0.00016	0.00169	CcSEcCtD
Nilotinib—Pruritus—Temozolomide—malignant glioma	0.00016	0.00169	CcSEcCtD
Nilotinib—CA2—spinal cord—malignant glioma	0.000158	0.00159	CbGeAlD
Nilotinib—CA1—brain—malignant glioma	0.000157	0.00158	CbGeAlD
Nilotinib—Dizziness—Carmustine—malignant glioma	0.000155	0.00163	CcSEcCtD
Nilotinib—Diarrhoea—Temozolomide—malignant glioma	0.000155	0.00163	CcSEcCtD
Nilotinib—CA4—central nervous system—malignant glioma	0.000154	0.00156	CbGeAlD
Nilotinib—CA4—cerebellum—malignant glioma	0.000151	0.00152	CbGeAlD
Nilotinib—ABCG2—midbrain—malignant glioma	0.00015	0.00151	CbGeAlD
Nilotinib—Dizziness—Temozolomide—malignant glioma	0.00015	0.00158	CcSEcCtD
Nilotinib—ABL1—brain—malignant glioma	0.000149	0.00151	CbGeAlD
Nilotinib—Vomiting—Carmustine—malignant glioma	0.000149	0.00157	CcSEcCtD
Nilotinib—Rash—Carmustine—malignant glioma	0.000148	0.00156	CcSEcCtD
Nilotinib—Dermatitis—Carmustine—malignant glioma	0.000148	0.00156	CcSEcCtD
Nilotinib—Headache—Carmustine—malignant glioma	0.000147	0.00155	CcSEcCtD
Nilotinib—ABCG2—spinal cord—malignant glioma	0.000146	0.00147	CbGeAlD
Nilotinib—Vomiting—Temozolomide—malignant glioma	0.000144	0.00152	CcSEcCtD
Nilotinib—CYP2D6—telencephalon—malignant glioma	0.000143	0.00144	CbGeAlD
Nilotinib—Rash—Temozolomide—malignant glioma	0.000143	0.0015	CcSEcCtD
Nilotinib—Dermatitis—Temozolomide—malignant glioma	0.000143	0.0015	CcSEcCtD
Nilotinib—Headache—Temozolomide—malignant glioma	0.000142	0.00149	CcSEcCtD
Nilotinib—Nausea—Carmustine—malignant glioma	0.000139	0.00147	CcSEcCtD
Nilotinib—Nausea—Temozolomide—malignant glioma	0.000135	0.00142	CcSEcCtD
Nilotinib—CA2—central nervous system—malignant glioma	0.000128	0.00129	CbGeAlD
Nilotinib—ABCB1—embryo—malignant glioma	0.000127	0.00128	CbGeAlD
Nilotinib—CA2—cerebellum—malignant glioma	0.000125	0.00126	CbGeAlD
Nilotinib—CA4—brain—malignant glioma	0.000123	0.00124	CbGeAlD
Nilotinib—ABCG2—cerebellum—malignant glioma	0.000116	0.00117	CbGeAlD
Nilotinib—ABCB1—retina—malignant glioma	0.000112	0.00113	CbGeAlD
Nilotinib—CYP2B6—central nervous system—malignant glioma	0.000109	0.0011	CbGeAlD
Nilotinib—ABCB1—telencephalon—malignant glioma	0.000103	0.00104	CbGeAlD
Nilotinib—CA2—brain—malignant glioma	0.000102	0.00102	CbGeAlD
Nilotinib—CYP2C8—brain—malignant glioma	9.69e-05	0.000976	CbGeAlD
Nilotinib—ABCG2—brain—malignant glioma	9.42e-05	0.000949	CbGeAlD
Nilotinib—CYP2B6—brain—malignant glioma	8.69e-05	0.000876	CbGeAlD
Nilotinib—CYP3A4—central nervous system—malignant glioma	8.26e-05	0.000833	CbGeAlD
Nilotinib—CYP2D6—central nervous system—malignant glioma	8.13e-05	0.00082	CbGeAlD
Nilotinib—ABCB1—medulla oblongata—malignant glioma	8.09e-05	0.000815	CbGeAlD
Nilotinib—CYP2D6—cerebellum—malignant glioma	7.95e-05	0.000801	CbGeAlD
Nilotinib—ABCB1—midbrain—malignant glioma	7.39e-05	0.000745	CbGeAlD
Nilotinib—ABCB1—spinal cord—malignant glioma	7.21e-05	0.000727	CbGeAlD
Nilotinib—CYP2D6—brain—malignant glioma	6.46e-05	0.000651	CbGeAlD
Nilotinib—ABCB1—central nervous system—malignant glioma	5.85e-05	0.00059	CbGeAlD
Nilotinib—ABCB1—cerebellum—malignant glioma	5.72e-05	0.000576	CbGeAlD
Nilotinib—ABCB1—brain—malignant glioma	4.64e-05	0.000468	CbGeAlD
Nilotinib—LCK—Signaling Pathways—PIK3CG—malignant glioma	1.53e-06	7.51e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APC—malignant glioma	1.53e-06	7.51e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PIK3CA—malignant glioma	1.53e-06	7.5e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.53e-06	7.49e-06	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—malignant glioma	1.52e-06	7.47e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGF—malignant glioma	1.51e-06	7.42e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KRAS—malignant glioma	1.5e-06	7.38e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTPN11—malignant glioma	1.5e-06	7.38e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MDM2—malignant glioma	1.5e-06	7.37e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KRAS—malignant glioma	1.5e-06	7.36e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—MYC—malignant glioma	1.5e-06	7.35e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—MYC—malignant glioma	1.5e-06	7.35e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—RAF1—malignant glioma	1.5e-06	7.34e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CASP3—malignant glioma	1.49e-06	7.32e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—PIK3CA—malignant glioma	1.49e-06	7.32e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—FGF2—malignant glioma	1.49e-06	7.31e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL2—malignant glioma	1.49e-06	7.31e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MMP9—malignant glioma	1.49e-06	7.31e-06	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—malignant glioma	1.49e-06	7.31e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—malignant glioma	1.48e-06	7.28e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—NCOR1—malignant glioma	1.48e-06	7.27e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB2—malignant glioma	1.48e-06	7.26e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTEN—malignant glioma	1.48e-06	7.26e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—malignant glioma	1.47e-06	7.23e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MDM2—malignant glioma	1.47e-06	7.21e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—malignant glioma	1.47e-06	7.21e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STAT3—malignant glioma	1.47e-06	7.2e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—KRAS—malignant glioma	1.47e-06	7.2e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—malignant glioma	1.47e-06	7.19e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—RAF1—malignant glioma	1.47e-06	7.19e-06	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—malignant glioma	1.46e-06	7.18e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KRAS—malignant glioma	1.46e-06	7.17e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CB—malignant glioma	1.46e-06	7.17e-06	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—malignant glioma	1.46e-06	7.14e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STAT3—malignant glioma	1.45e-06	7.14e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PIK3CA—malignant glioma	1.45e-06	7.13e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB2—malignant glioma	1.45e-06	7.11e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PTEN—malignant glioma	1.45e-06	7.1e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—BRAF—malignant glioma	1.44e-06	7.06e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CB—malignant glioma	1.43e-06	7.02e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CAV1—malignant glioma	1.43e-06	7e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PIK3CA—malignant glioma	1.41e-06	6.93e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MMP9—malignant glioma	1.41e-06	6.92e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—malignant glioma	1.41e-06	6.9e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—GSTP1—malignant glioma	1.4e-06	6.89e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—malignant glioma	1.4e-06	6.89e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—malignant glioma	1.4e-06	6.88e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTEN—malignant glioma	1.4e-06	6.88e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT2—malignant glioma	1.4e-06	6.87e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MDM2—malignant glioma	1.39e-06	6.84e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—malignant glioma	1.39e-06	6.83e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—RAF1—malignant glioma	1.39e-06	6.81e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—malignant glioma	1.38e-06	6.79e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTEN—malignant glioma	1.38e-06	6.79e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PIK3CA—malignant glioma	1.38e-06	6.78e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PIK3CA—malignant glioma	1.38e-06	6.76e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—malignant glioma	1.37e-06	6.74e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB2—malignant glioma	1.37e-06	6.74e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAT—malignant glioma	1.37e-06	6.71e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MYC—malignant glioma	1.36e-06	6.69e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CB—malignant glioma	1.36e-06	6.66e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CB—malignant glioma	1.36e-06	6.65e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—malignant glioma	1.35e-06	6.63e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—malignant glioma	1.35e-06	6.62e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTGS2—malignant glioma	1.35e-06	6.6e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CD—malignant glioma	1.35e-06	6.6e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—malignant glioma	1.34e-06	6.59e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—malignant glioma	1.34e-06	6.59e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—malignant glioma	1.34e-06	6.58e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—malignant glioma	1.34e-06	6.57e-06	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—malignant glioma	1.34e-06	6.57e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—malignant glioma	1.34e-06	6.56e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—malignant glioma	1.34e-06	6.56e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—malignant glioma	1.33e-06	6.55e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.33e-06	6.53e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—malignant glioma	1.32e-06	6.5e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—GSTP1—malignant glioma	1.32e-06	6.49e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—malignant glioma	1.32e-06	6.49e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—malignant glioma	1.32e-06	6.47e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—malignant glioma	1.32e-06	6.46e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—malignant glioma	1.31e-06	6.45e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—GSTP1—malignant glioma	1.31e-06	6.44e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—malignant glioma	1.3e-06	6.39e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CG—malignant glioma	1.3e-06	6.38e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—malignant glioma	1.29e-06	6.35e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—NCOR1—malignant glioma	1.29e-06	6.33e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAT—malignant glioma	1.29e-06	6.32e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—FGF2—malignant glioma	1.29e-06	6.32e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—malignant glioma	1.28e-06	6.27e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAT—malignant glioma	1.28e-06	6.26e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—malignant glioma	1.27e-06	6.25e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—malignant glioma	1.27e-06	6.24e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—malignant glioma	1.27e-06	6.23e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—malignant glioma	1.27e-06	6.21e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—malignant glioma	1.26e-06	6.19e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—malignant glioma	1.26e-06	6.19e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—malignant glioma	1.25e-06	6.15e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—malignant glioma	1.25e-06	6.15e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—malignant glioma	1.25e-06	6.13e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—malignant glioma	1.25e-06	6.13e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTT1—malignant glioma	1.25e-06	6.13e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—malignant glioma	1.25e-06	6.12e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—malignant glioma	1.25e-06	6.11e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—malignant glioma	1.24e-06	6.1e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—malignant glioma	1.24e-06	6.06e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—malignant glioma	1.23e-06	6.04e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—malignant glioma	1.22e-06	5.98e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—NCOR1—malignant glioma	1.22e-06	5.97e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAV1—malignant glioma	1.21e-06	5.93e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—NCOR1—malignant glioma	1.21e-06	5.92e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MDM2—malignant glioma	1.21e-06	5.91e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—malignant glioma	1.2e-06	5.9e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—malignant glioma	1.2e-06	5.9e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—malignant glioma	1.2e-06	5.9e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—RAF1—malignant glioma	1.2e-06	5.89e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—malignant glioma	1.19e-06	5.83e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—malignant glioma	1.19e-06	5.83e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—malignant glioma	1.18e-06	5.78e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—malignant glioma	1.18e-06	5.77e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—malignant glioma	1.17e-06	5.76e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CB—malignant glioma	1.17e-06	5.75e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—malignant glioma	1.17e-06	5.75e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS1—malignant glioma	1.17e-06	5.74e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—malignant glioma	1.16e-06	5.71e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—malignant glioma	1.16e-06	5.68e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.15e-06	5.66e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—malignant glioma	1.15e-06	5.66e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—malignant glioma	1.15e-06	5.63e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CD—malignant glioma	1.14e-06	5.6e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—malignant glioma	1.14e-06	5.59e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—malignant glioma	1.14e-06	5.59e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—malignant glioma	1.14e-06	5.58e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—malignant glioma	1.13e-06	5.54e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—malignant glioma	1.13e-06	5.54e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—malignant glioma	1.13e-06	5.53e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—malignant glioma	1.13e-06	5.52e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—malignant glioma	1.12e-06	5.5e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—malignant glioma	1.12e-06	5.48e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—malignant glioma	1.11e-06	5.45e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—malignant glioma	1.11e-06	5.45e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—malignant glioma	1.11e-06	5.42e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—malignant glioma	1.11e-06	5.42e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—malignant glioma	1.1e-06	5.41e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CG—malignant glioma	1.1e-06	5.4e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—malignant glioma	1.1e-06	5.38e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—BCHE—malignant glioma	1.09e-06	5.34e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—malignant glioma	1.08e-06	5.29e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—malignant glioma	1.08e-06	5.28e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—malignant glioma	1.08e-06	5.28e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.07e-06	5.27e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—malignant glioma	1.06e-06	5.21e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—malignant glioma	1.06e-06	5.19e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAV1—malignant glioma	1.05e-06	5.16e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—malignant glioma	1.05e-06	5.15e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—malignant glioma	1.05e-06	5.14e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—malignant glioma	1.04e-06	5.12e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—malignant glioma	1.04e-06	5.12e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—malignant glioma	1.04e-06	5.1e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—malignant glioma	1.04e-06	5.1e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—malignant glioma	1.03e-06	5.04e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—malignant glioma	1.03e-06	5.03e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—malignant glioma	1.02e-06	5.01e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—malignant glioma	1.02e-06	5e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—malignant glioma	1.01e-06	4.97e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—malignant glioma	1.01e-06	4.96e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—malignant glioma	1e-06	4.93e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CB—malignant glioma	9.96e-07	4.89e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAV1—malignant glioma	9.92e-07	4.86e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—malignant glioma	9.89e-07	4.85e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTGS2—malignant glioma	9.87e-07	4.84e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAV1—malignant glioma	9.83e-07	4.82e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—malignant glioma	9.76e-07	4.79e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—malignant glioma	9.74e-07	4.78e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—malignant glioma	9.7e-07	4.76e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CD—malignant glioma	9.67e-07	4.75e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CG—malignant glioma	9.59e-07	4.7e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—malignant glioma	9.57e-07	4.69e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—malignant glioma	9.53e-07	4.67e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—malignant glioma	9.49e-07	4.66e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—malignant glioma	9.46e-07	4.64e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	9.39e-07	4.61e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—malignant glioma	9.37e-07	4.6e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—malignant glioma	9.25e-07	4.54e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—malignant glioma	9.15e-07	4.49e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—malignant glioma	9.06e-07	4.45e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CG—malignant glioma	9.03e-07	4.43e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—malignant glioma	9.03e-07	4.43e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—malignant glioma	9e-07	4.41e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CG—malignant glioma	8.95e-07	4.39e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—malignant glioma	8.91e-07	4.37e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—malignant glioma	8.72e-07	4.28e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—malignant glioma	8.72e-07	4.28e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—GSTP1—malignant glioma	8.65e-07	4.25e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—malignant glioma	8.64e-07	4.24e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—malignant glioma	8.62e-07	4.23e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—malignant glioma	8.61e-07	4.22e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—malignant glioma	8.53e-07	4.19e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—malignant glioma	8.44e-07	4.14e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CB—malignant glioma	8.43e-07	4.14e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CD—malignant glioma	8.43e-07	4.13e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAT—malignant glioma	8.42e-07	4.13e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—malignant glioma	8.42e-07	4.13e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTGS2—malignant glioma	8.35e-07	4.1e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—malignant glioma	8.34e-07	4.09e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—malignant glioma	8.28e-07	4.06e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—malignant glioma	8.27e-07	4.06e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—malignant glioma	8.24e-07	4.04e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—malignant glioma	8.08e-07	3.96e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—malignant glioma	8e-07	3.92e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—malignant glioma	7.97e-07	3.91e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—NCOR1—malignant glioma	7.95e-07	3.9e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CD—malignant glioma	7.94e-07	3.9e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CD—malignant glioma	7.87e-07	3.86e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—malignant glioma	7.78e-07	3.82e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CB—malignant glioma	7.34e-07	3.6e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—malignant glioma	7.29e-07	3.57e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTGS2—malignant glioma	7.28e-07	3.57e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—malignant glioma	7.28e-07	3.57e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—malignant glioma	7.15e-07	3.51e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—malignant glioma	7.12e-07	3.5e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CB—malignant glioma	6.92e-07	3.4e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—malignant glioma	6.92e-07	3.39e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CB—malignant glioma	6.86e-07	3.37e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTGS2—malignant glioma	6.86e-07	3.36e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTGS2—malignant glioma	6.8e-07	3.34e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—malignant glioma	6.77e-07	3.32e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—malignant glioma	6.75e-07	3.31e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAV1—malignant glioma	6.48e-07	3.18e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—malignant glioma	6.35e-07	3.11e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—malignant glioma	6.07e-07	2.98e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—malignant glioma	5.98e-07	2.93e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—malignant glioma	5.93e-07	2.91e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CG—malignant glioma	5.91e-07	2.9e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—malignant glioma	5.84e-07	2.86e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—malignant glioma	5.7e-07	2.8e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CD—malignant glioma	5.19e-07	2.55e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—malignant glioma	5.14e-07	2.52e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—malignant glioma	4.96e-07	2.43e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CB—malignant glioma	4.53e-07	2.22e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTGS2—malignant glioma	4.48e-07	2.2e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—malignant glioma	4.48e-07	2.2e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—malignant glioma	4.22e-07	2.07e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—malignant glioma	4.2e-07	2.06e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—malignant glioma	4.18e-07	2.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—malignant glioma	3.91e-07	1.92e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—malignant glioma	3.66e-07	1.79e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—malignant glioma	3.45e-07	1.69e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—malignant glioma	3.42e-07	1.68e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—malignant glioma	2.76e-07	1.35e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—malignant glioma	2.25e-07	1.11e-06	CbGpPWpGaD
